➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Medtronic
Colorcon
Baxter
Moodys

Last Updated: June 13, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Trastuzumab emtansine


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Trastuzumab emtansine?

Trastuzumab emtansine is an investigational drug.

There have been 88 clinical trials for Trastuzumab emtansine. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2016.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, and Neoplasms. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and Dana-Farber Cancer Institute.

There are forty-eight US patents protecting this investigational drug and nine hundred and two international patents.

Recent Clinical Trials for Trastuzumab emtansine
TitleSponsorPhase
ATEMPT 2.0: Adjuvant T-DM1 vs THGenentech, Inc.Phase 2
ATEMPT 2.0: Adjuvant T-DM1 vs THDana-Farber Cancer InstitutePhase 2
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative TherapyHoffmann-La RochePhase 3

See all Trastuzumab emtansine clinical trials

Clinical Trial Summary for Trastuzumab emtansine

Top disease conditions for Trastuzumab emtansine
Top clinical trial sponsors for Trastuzumab emtansine

See all Trastuzumab emtansine clinical trials

US Patents for Trastuzumab emtansine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Trastuzumab emtansine   Get Started Free Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds Array BioPharma Inc. (Boulder, CO)   Get Started Free
Trastuzumab emtansine   Get Started Free Methods for the treatment of HER2 amplified cancer Pharmacyclics LLC (Sunnyvale, CA)   Get Started Free
Trastuzumab emtansine   Get Started Free Encapsulated agents and methods of making and using thereof University of Georgia Research Foundation, Inc. (Athens, GA)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Trastuzumab emtansine

Drugname Country Document Number Estimated Expiration Related US Patent
Trastuzumab emtansine Argentina AR074052 2028-10-22   Get Started Free
Trastuzumab emtansine Argentina AR112833 2028-10-22   Get Started Free
Trastuzumab emtansine Australia AU2009308465 2028-10-22   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Baxter
McKesson
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.